Literature DB >> 18781900

Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS).

Suzanne V Frankfort1, Jos P C M van Campen, Linda R Tulner, Jos H Beijnen.   

Abstract

BACKGROUND: By using surface enhanced laser desorption/ionisation- time of flight mass spectrometry (SELDI-TOF MS) an amyloid beta (Abeta) profile was shown in cerebrospinal fluid (CSF) of patients with dementia.
OBJECTIVE: To investigate the Abeta-profile in serum with SELDI-TOF MS, to evaluate if this profile resembles CSF profiles and to investigate the correlation between intensity of Abeta-peptide-peaks in serum and clinical, demographical and genetic variables.
METHODS: Duplicate profiling of Abeta by an SELDI-TOF MS immunocapture assay was performed in 106 patients, suffering from Alzheimer's Disease or Vascular Dementia and age-matched non-demented control patients. Linear regression analyses were performed to investigate the intensities of four selected Abeta peaks as dependent variables in relation to the independent clinical, demographic or genetic variables.
RESULTS: Abeta37, Abeta38 and Abeta40 were found among additional unidentified Abeta peptides, with the most pronounced Abeta peak at a molecular mass of 7752. This profile partly resembled the CSF profile. The clinical diagnosis was not a predictive independent variable, however ABCB1 genotypes C1236T, G2677T/A, age and creatinine level showed to be related to Abeta peak intensities in multivariate analyses.
CONCLUSIONS: We found an Abeta profile in serum that partly resembled the CSF profile in demented patients. Age, creatinine levels, presence of the APOE epsilon4 allele and ABCB1 genotypes (C1236T and G2677T/A) were correlated with the Abeta serum profile. The role of P-gp as an Abeta transporter and the role of ABCB1 genotypes deserves further research. The investigated serum Abeta profile is probably not useful in the diagnosis of dementia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781900     DOI: 10.2174/157488408785747665

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  5 in total

1.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

2.  ABCB1 C3435T polymorphism influences the risk for Alzheimer's disease.

Authors:  Ágnes Fehér; Anna Juhász; Magdolna Pákáski; János Kálmán; Zoltán Janka
Journal:  J Mol Neurosci       Date:  2014-10-02       Impact factor: 3.444

3.  Novel possibilities in the study of the salivary proteomic profile using SELDI-TOF/MS technology.

Authors:  Fatima Ardito; Donatella Perrone; Roberto Cocchi; Lucio Lo Russo; Alfredo DE Lillo; Giovanni Giannatempo; Lorenzo Lo Muzio
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

Review 4.  Identifying and validating biomarkers for Alzheimer's disease.

Authors:  Christian Humpel
Journal:  Trends Biotechnol       Date:  2010-10-23       Impact factor: 19.536

5.  [Not Available].

Authors:  Sandra K Al-Tarawneh; Sompop Bencharit
Journal:  Open Dent J       Date:  2009-04-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.